Results 81 to 90 of about 7,378 (198)

Once-Daily MMX (R) Mesalamine for Endoscopic Maintenance of Remission of Ulcerative Colitis

, 2012
OBJECTIVES: Treatment with mesalamine to maintain endoscopic remission (mucosal healing) of ulcerative colitis (UC) has been shown to reduce the risk of relapse and is the recommended first-line maintenance therapy.
Streck, Paul, Sandborn, William J., D'Haens, Geert, Barrett, Karen, Hodgson, Ian   +4 more
core   +1 more source

Therapeutic potential of mesalamine-probiotic combination in enteric-coated tablet for modulating gut inflammation in IBD

Journal of Applied Pharmaceutical Research
Background: Mesalamine is widely used for inflammatory bowel disease (IBD) due to its local anti-inflammatory action, while probiotics help restore intestinal microbiota and modulate immune responses. Combining both may offer synergistic benefits for IBD
Pratiksha A. Thete, Milind P. Wagh, Vandana S. Nade   +2 more
doaj   +1 more source

Innovative Rectal Suspension of Mesalamine Utilizing Mesoporous Silica for Sustained and Colon-Specific Drug Delivery : Novel rectal suspension of mesalamine

Mesalamine is an anti-inflammatory drug for the treatment of ulcerative colitis-related colon cancer. The present study aims to evaluate the rectal suspension of mesoporous mesalamine for improved localized effect of the drug in the ulcerative colon of ...
Prajapati, Rajnish Umesh, Bicchali, Usha, Bhattacharyya, Sayani   +2 more
core   +1 more source

A rare case of mesalamine-induced eosinophilic pleural effusion

The Journal of Association of Chest Physicians
We present a very rare case of a 47-year-old man with a history of ulcerative colitis (UC), referred to as a case of an undiagnosed bilateral pleural effusion.
Ankit Bhatia, Sharad Joshi, Nitesh Tayal, Maj Gen Darshan Singh Bhakuni, Subhasish Majumdar   +4 more
doaj   +1 more source

Induction of oxidative DNA damage by mesalamine in the presence of copper: A potential mechanism for mesalamine anticancer activity Induction of Oxidative DNA Damage by Mesalamine in the Presence of Copper: A Potential Mechanism for

, 2020
: Mesalamine is the first line pharmacologic intervention for patients with ulcerative colitis, and recent epidemiologic studies have demonstrated a protective association between therapeutic use of the drug and colorectal carcinoma.
Nathan Vandjelovic, Zhu H, Jianmin Wang, Vandjelovic N, Yunbo Li, Zimmerman Rp, Zhenquan Jia, Ryan P Zimmerman, Wang J Li, Y, Misra Hp, Hara P Misra, Hong Zhu, Jia Z   +13 more
core  

Simple one-pot green method for large-scale production of mesalamine, an anti-inflammatory agent

Green Processing and Synthesis, 2019
We report a rapid and efficient synthesis protocol for mesalamine via a green approach with 2-chloro-5-nitrobenzoic acid as the starting material, for its large-scale production.
Vijaya Lakshmi C., Katari Naresh Kumar, Jonnalagadda Sreekantha B.   +2 more
doaj   +1 more source

Formulation and Characterization of Mesalamine Pellets [PDF]

, 2019
The present work describes a study on “Formulation and Characterization of Mesalamine pellets” Mesalamine is an amino salicylate used for the treatment of inflammatory bowel disease including ulcerative colitis and crohn’s disease. Mesalamine diminishes
Anitha, G
core  

CODEN: RJCABP LARGE SCALE PROCESS OF MESALAMINE GREEN APPROACH FOR LARGE SCALE PROCESS OF MESALAMINE: AN ANTI INFLAMMATORY AGENT

, 2009
Mesalamine 1 is as an anti inflammatory agent in treating ulcerative colitis and crohn's disease. Its benefit is believed to be due to a topical effect on the inflamed bowel.
Jaydeepkumar Lilakar, Neti Srinivasan
core  

Higher education, professional occupation, and upper socioeconomic status are associated with lower adherence to medications in patients with inflammatory bowel disease

JGH Open, 2019
Background and Aim The literature on medication adherence in patients with inflammatory bowel disease (IBD) is heterogeneous. The present study aimed to identify the rates and predictors of nonadherence to medications in IBD. Methods This cross‐sectional
Sanjeevani K Tomar, Saurabh Kedia, Namrata Singh, Ashish D Upadhyay, Nagesh Kamat, Sawan Bopanna, Dawesh P Yadav, Sandeep Goyal, Saransh Jain, Govind Makharia, Vineet Ahuja   +10 more
doaj   +1 more source

Mesalamine Did Not Prevent Recurrent Diverticulitis in Phase 3 Controlled Trials

, 2014
No therapy has been proven to prevent the recurrence of diverticulitis. Mesalamine has shown efficacy in preventing relapse in inflammatory bowel disease, and there is preliminary evidence that it might be effective for diverticular disease.
Kamm, Michael A, Raskin, Jeffrey B, Szalóki, Tibor, Barrett, Karen, Márquez, Juan, Schoen, Robert E, Melzer, Ehud, Jamal, M. Mazen, Streck, Paul   +8 more
core   +1 more source